Material polarity determines compound migration patterns - semi-polar substances represent the middle ground between water-soluble and lipophilic extractables, requiring intermediate polarity solvents for comprehensive detection. Semi-polar non-volatile compound screening using isopropanol extraction followed by LC-MS provides comprehensive characterization of moderately polar, non-volatile substances occupying the intermediate polarity range between water-soluble and lipophilic extractables. This ISO 10993-12 and 10993-18 compliant analysis captures additives with intermediate polarity including plasticizers and stabilizers, oligomers from polymer processing, and degradation products formed through oxidation or hydrolysis reactions. The isopropanol extraction effectively solubilizes semi-polar compounds while maintaining compatibility with LC-MS analysis through appropriate dilution or solvent exchange, enabling direct injection without extensive sample preparation. Critical for devices containing polyurethanes where semi-polar additives enable processing and provide material properties, modified polymers with grafted functional groups creating intermediate polarity, and materials with complex additive packages requiring comprehensive characterization across polarity ranges. The LC-MS methodology accommodates compounds too polar for GC analysis yet not sufficiently ionic for standard reverse-phase LC, using gradient elution separating compounds across wide polarity range. Manufacturing validation confirms that processing removes semi-polar solvents used in fabrication, sterilization doesn't generate semi-polar degradation products, and aging doesn't produce oxidation products requiring safety assessment. For implantable devices, semi-polar extractables assessment characterizes chronic exposure to moderately polar compounds that accumulate at implant-tissue interfaces, while cardiovascular devices need screening ensuring blood contact doesn't extract harmful semi-polar additives.

Lipophilic non-volatile compounds represent the most challenging extractables - high molecular weight hydrophobic substances resist both aqueous extraction and GC analysis, requiring aggressive organic extraction and LC-MS for detection. Non-polar extraction using hexane followed by LC-MS analysis targets lipophilic, non-volatile compounds that complement GC-MS screening by capturing high molecular weight hydrophobic substances resistant to volatilization. Following ISO 10993-12 and 10993-18 requirements, this approach captures non-volatile plasticizers providing flexibility without vapor pressure, complex lipophilic additives including stabilizer packages and UV absorbers, and high molecular weight hydrophobic components that standard GC methods cannot analyze. Essential for devices with rubber components containing non-volatile additives including polymeric plasticizers and high molecular weight antioxidants, silicone devices with high molecular weight components like PDMS oligomers, and materials where comprehensive characterization requires both volatile and non-volatile analysis spanning full molecular weight range. The hexane extraction aggressively solubilizes lipophilic substances providing worst-case assessment, while LC-MS enables analysis of high molecular weight compounds through softer ionization preventing fragmentation. For implantable devices, non-volatile lipophilic extractables accumulate in fatty tissues surrounding implants creating chronic exposure scenarios requiring characterization, while blood-contacting devices need assessment ensuring lipophilic compounds don't partition into lipoproteins causing systemic distribution. The analysis proves particularly valuable when investigating cytotoxicity potentially caused by high molecular weight extractables that volatile screening misses, validating new polymers with unknown additive compositions, or qualifying alternative suppliers whose formulations differ from established materials.

Medical cannabis products require precise cannabinoid quantification for therapeutic efficacy, regulatory compliance, and patient safety - THC and CBD ratios determine pharmacological effects while regulatory limits prevent psychoactive exposure. Comprehensive cannabinoid profiling following Swissmedic requirements quantifies THC, CBD, and related compounds in medical cannabis products through GC-MS analysis distinguishing between psychoactive and therapeutic cannabinoids. This analysis ensures products meet regulatory limits with THC quantification confirming levels remain below psychoactive thresholds for CBD products, CBD quantification validating therapeutic content matching labeled claims, and related cannabinoid profiling providing complete chemical characterization. Critical for medical cannabis quality control ensuring batch-to-batch consistency in cannabinoid content, validating THC levels remain below legal limits in CBD products preventing psychoactive effects, and supporting product registration for cannabis-based medicines requiring comprehensive cannabinoid characterization. The GC-MS methodology provides definitive cannabinoid identification through mass spectral confirmation, quantifies major cannabinoids including THC, CBD, CBN, and CBG providing complete profiles, and detects degradation products indicating improper storage or aging. For pharmaceutical cannabis applications, cannabinoid profiling validates extraction processes achieve target cannabinoid ratios, demonstrates stability throughout shelf life maintaining therapeutic potency, and supports dosing claims ensuring patients receive consistent cannabinoid exposure. Swiss medical cannabis regulations require documented cannabinoid testing for product authorization with ongoing batch release testing maintaining compliance, while international markets increasingly demand similar data for medical cannabis product approval.